Loading...

Celldex Therapeutics

Nasdaq:CLDX
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CLDX
Nasdaq
$46M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • Celldex Therapeutics has significant price volatility in the past 3 months.
CLDX Share Price and Events
7 Day Returns
-6%
NasdaqCM:CLDX
-5.7%
US Biotechs
-3.9%
US Market
1 Year Returns
-68.2%
NasdaqCM:CLDX
-7.9%
US Biotechs
1.4%
US Market
CLDX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Celldex Therapeutics (CLDX) -6% -18.3% -43.5% -68.2% -94.3% -98.3%
US Biotechs -5.7% -8.7% -6.4% -7.9% 5.5% 10.5%
US Market -3.9% -3.6% 1.8% 1.4% 35.8% 40.8%
1 Year Return vs Industry and Market
  • CLDX underperformed the Biotechs industry which returned -7.9% over the past year.
  • CLDX underperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
CLDX
Industry
5yr Volatility vs Market

Value

 Is Celldex Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Celldex Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $3.31.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Celldex Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Celldex Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:CLDX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-4.50
NasdaqCM:CLDX Share Price ** NasdaqCM (2019-05-15) in USD $3.31
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.35x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Celldex Therapeutics.

NasdaqCM:CLDX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CLDX Share Price ÷ EPS (both in USD)

= 3.31 ÷ -4.50

-0.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celldex Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Celldex Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Celldex Therapeutics's expected growth come at a high price?
Raw Data
NasdaqCM:CLDX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-12.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.15x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Celldex Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Celldex Therapeutics's assets?
Raw Data
NasdaqCM:CLDX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $8.77
NasdaqCM:CLDX Share Price * NasdaqCM (2019-05-15) in USD $3.31
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.11x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqCM:CLDX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CLDX Share Price ÷ Book Value per Share (both in USD)

= 3.31 ÷ 8.77

0.38x

* Primary Listing of Celldex Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celldex Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Celldex Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Celldex Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Celldex Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Celldex Therapeutics expected to grow at an attractive rate?
  • Unable to compare Celldex Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Celldex Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Celldex Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:CLDX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:CLDX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -12.4%
NasdaqCM:CLDX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 13.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:CLDX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:CLDX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 -95
2022-12-31 9 -86 1
2021-12-31 9 -74 1
2020-12-31 6 -68 1
2019-12-31 5 -62 1
NasdaqCM:CLDX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 7 -60 -50
2018-12-31 10 -75 -151
2018-09-30 11 -79 -146
2018-06-30 14 -89 -165
2018-03-31 15 -93 -177
2017-12-31 13 -100 -93
2017-09-30 11 -101 -121
2017-06-30 9 -100 -125
2017-03-31 7 -113 -128
2016-12-31 7 -113 -129
2016-09-30 7 -106 -129
2016-06-30 6 -110 -131

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Celldex Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Celldex Therapeutics's revenue is expected to grow by 13.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:CLDX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Celldex Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CLDX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -4.19 -4.19 -4.19 1.00
2022-12-31 -3.92 -3.92 -3.92 1.00
2021-12-31 -3.84 -3.84 -3.84 1.00
2020-12-31 -3.69 -3.69 -3.69 1.00
2019-12-31 -4.80 -4.80 -4.80 1.00
NasdaqCM:CLDX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -4.50
2018-12-31 -14.48
2018-09-30 -14.85
2018-06-30 -17.83
2018-03-31 -19.95
2017-12-31 -10.86
2017-09-30 -15.02
2017-06-30 -16.40
2017-03-31 -17.87
2016-12-31 -18.99
2016-09-30 -19.49
2016-06-30 -19.95

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Celldex Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Celldex Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Celldex Therapeutics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Celldex Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Celldex Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Celldex Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Celldex Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Celldex Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Celldex Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Celldex Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CLDX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 6.90 -50.29 18.57 -10.72
2018-12-31 9.54 -151.18 19.27
2018-09-30 11.23 -145.62 20.83
2018-06-30 14.21 -164.74 22.46
2018-03-31 15.28 -176.90 23.37
2017-12-31 12.74 -93.03 25.00
2017-09-30 11.16 -121.50 27.44
2017-06-30 9.46 -124.73 29.05
2017-03-31 7.02 -128.12 30.30
2016-12-31 6.79 -128.53 33.58
2016-09-30 6.70 -128.91 35.13
2016-06-30 5.51 -131.29 36.66
2016-03-31 6.30 -131.70 37.06
2015-12-31 5.48 -127.20 33.84
2015-09-30 5.17 -126.34 29.01
2015-06-30 5.24 -122.44 25.53
2015-03-31 3.66 -118.35 22.13
2014-12-31 3.59 -118.08 20.62
2014-09-30 2.73 -108.32 19.05
2014-06-30 2.61 -103.38 17.63
2014-03-31 2.11 -94.12 16.25
2013-12-31 4.11 -81.55 14.81
2013-09-30 7.14 -76.30 12.77
2013-06-30 9.27 -68.18 12.03
2013-03-31 11.18 -62.94 10.84
2012-12-31 11.20 -59.12 10.02
2012-09-30 9.99 -55.05 12.22
2012-06-30 9.24 -51.79 11.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Celldex Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Celldex Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Celldex Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Celldex Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Celldex Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Celldex Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Celldex Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Celldex Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Celldex Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Celldex Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Celldex Therapeutics Company Filings, last reported 1 month ago.

NasdaqCM:CLDX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 112.69 5.23 85.07
2018-12-31 124.06 0.00 94.02
2018-09-30 128.13 0.00 105.62
2018-06-30 128.05 0.00 114.01
2018-03-31 134.08 0.00 123.25
2017-12-31 236.37 0.00 139.43
2017-09-30 219.15 0.00 140.53
2017-06-30 231.46 0.00 153.98
2017-03-31 247.84 0.00 167.02
2016-12-31 265.43 0.00 189.78
2016-09-30 217.09 0.00 203.25
2016-06-30 234.71 0.00 220.13
2016-03-31 260.03 0.00 254.02
2015-12-31 290.11 0.00 289.89
2015-09-30 318.63 0.00 304.61
2015-06-30 345.88 0.00 333.99
2015-03-31 375.55 0.00 359.77
2014-12-31 211.66 0.00 201.04
2014-09-30 239.37 0.00 224.08
2014-06-30 265.32 0.00 252.37
2014-03-31 291.85 0.00 274.23
2013-12-31 319.80 0.00 302.98
2013-09-30 156.75 0.43 136.59
2013-06-30 177.09 0.44 154.98
2013-03-31 194.94 10.51 182.38
2012-12-31 95.77 11.81 83.96
2012-09-30 91.02 13.11 77.62
2012-06-30 94.55 14.40 78.67
  • Celldex Therapeutics's level of debt (4.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 4.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Celldex Therapeutics has sufficient cash runway for 1.4 years based on current free cash flow.
  • Celldex Therapeutics has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -15.4% each year.
X
Financial health checks
We assess Celldex Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Celldex Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Celldex Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Celldex Therapeutics dividends.
If you bought $2,000 of Celldex Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Celldex Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Celldex Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:CLDX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:CLDX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Celldex Therapeutics has not reported any payouts.
  • Unable to verify if Celldex Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Celldex Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Celldex Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Celldex Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Celldex Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Celldex Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Celldex Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anthony Marucci
COMPENSATION $1,385,351
AGE 56
TENURE AS CEO 10.7 years
CEO Bio

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. Mr. Marucci Founded Celldex Therapeutics Inc. in May 2003. Mr. Marucci served as a Treasurer of BioNJ Inc. until 2010. He served as an Interim Chief Executive Officer and Interim President of Celldex Therapeutics Inc., from May 2008 to September 2008 and its Executive Vice President of Corporate Development from July 2008 to October 2008. Mr. Marucci served as the Chief Operating Officer, Principal Accounting Officer and Executive Vice President of Celldex Therapeutics, Inc., and its Executive Vice President of Corporate Development since March 2008 and Acting Chief Executive Officer since October 2007. He served as the Chief Financial Officer, Treasurer and Secretary of Celldex Therapeutics, Inc. since May 2003. Mr. Marucci held a series of senior financial positions at Medarex from December 1998 to May 2003. He served as a Treasurer of Medarex, Inc. (now a part of Bristol-Myers Squibb Co.) from December 1998 to March 2004. Mr. Marucci held a series of Senior Financial President of Medarex since December 1998. He has been a Director of Celldex Therapeutics Inc., since December 4, 2008. Mr. Marucci is a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci serves as a Trustee of BioNJ Inc. Mr. Marucci holds an MBA from Columbia University and his E.M.H.L. from Brown University.

CEO Compensation
  • Anthony's compensation has been consistent with company performance over the past year.
  • Anthony's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Celldex Therapeutics management team in years:

4.3
Average Tenure
55
Average Age
  • The tenure for the Celldex Therapeutics management team is about average.
Management Team

Anthony Marucci

TITLE
Founder
COMPENSATION
$1M
AGE
56
TENURE
10.7 yrs

Tibor Keler

TITLE
Founder
COMPENSATION
$749K
AGE
59
TENURE
16 yrs

Sam Martin

TITLE
Senior VP
COMPENSATION
$622K
AGE
47
TENURE
1.8 yrs

Elizabeth Crowley

TITLE
Chief Product Development Officer & Senior VP
COMPENSATION
$586K
AGE
46
TENURE
4.8 yrs

Margo Heath-Chiozzi

TITLE
Senior Vice President of Regulatory Affairs
COMPENSATION
$603K
AGE
61
TENURE
1.6 yrs

Sarah Cavanaugh

TITLE
Senior Vice President of Corporate Affairs & Administration
AGE
43
TENURE
1.9 yrs

Ronald Pepin

TITLE
Chief Business Officer & Senior VP
COMPENSATION
$2M
AGE
62
TENURE
7.8 yrs

Rick Wright

TITLE
Chief Commercial Officer & Senior VP
COMPENSATION
$563K
AGE
54
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the Celldex Therapeutics board of directors in years:

10
Average Tenure
66
Average Age
  • The average tenure for the Celldex Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Larry Ellberger

TITLE
Chairman
COMPENSATION
$127K
AGE
70
TENURE
9.7 yrs

Anthony Marucci

TITLE
Founder
COMPENSATION
$1M
AGE
56
TENURE
10.4 yrs

Karen Shoos

TITLE
Director
COMPENSATION
$88K
AGE
64
TENURE
18 yrs

Jim Marino

TITLE
Director
COMPENSATION
$90K
AGE
68
TENURE
2.2 yrs

Keith Brownlie

TITLE
Director
COMPENSATION
$94K
AGE
66
TENURE
1.9 yrs

Herb Conrad

TITLE
Director
COMPENSATION
$92K
AGE
85
TENURE
11.2 yrs

Louis Weiner

TITLE
Member of Scientific Advisory Board
AGE
66

Jeff Weber

TITLE
Member of Scientific Advisory Board

Randy Noelle

TITLE
Member of Scientific Advisory Board

Carl June

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
28. Aug 18 Buy James Marino Individual 24. Aug 18 24. Aug 18 2,667 $7.20 $19,200
18. Jun 18 Buy Tibor Keler Individual 15. Jun 18 15. Jun 18 1,100 $8.89 $9,783
X
Management checks
We assess Celldex Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Celldex Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.

Details
Name: Celldex Therapeutics, Inc.
CLDX
Exchange: NasdaqCM
Founded:
$45,574,986
13,768,878
Website: http://www.celldex.com
Address: Celldex Therapeutics, Inc.
Perryville III Building,
Suite 220,
Hampton,
New Jersey, 08827,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CLDX Common Stock with Par Value 0.001 Nasdaq Capital Market US USD 10. Mar 2008
DB TCE2 Common Stock with Par Value 0.001 Deutsche Boerse AG DE EUR 10. Mar 2008
Number of employees
Current staff
Staff numbers
134
Celldex Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 02:07
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2019/05/08
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.